Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for Waldenström macroglobulinemia (WM): An international collaborative study.
暂无分享，去创建一个
M. Dimopoulos | R. Kyle | Shaji K. Kumar | P. Morel | S. Treon | S. Ansell | M. Gertz | A. Delmer | E. Kastritis | E. Durot | J. Castillo | P. Cornillet‐Lefèbvre | S. Sarosiek | P. Kapoor | Encarl Uppal | J. Abeykoon | J. Paludo | S. D’Sa | M. O. Ogunbiyi | R. Tawfiq